Funding for this research was provided by:
Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium (NA)
Flanders Innovation & Entrepreneurship (VLAIO), Belgium (NA)
Received: 4 February 2020
Accepted: 2 April 2020
First Online: 14 May 2020
Ethics approval and consent to participate
: The study protocol and amendments were approved by the appropriate Independent Ethics Committee/Institutional Review Board. Written informed consent was obtained from all participants before their participation. All study procedures followed were in accordance with the current ICH guidelines on Good Clinical Practice (GCP), applicable regulatory and country-specific requirements, and the principals of the Declaration of Helsinki.
: Not applicable.
: All authors, except Dr. Engelborghs, report personal fees (current or former employment) from Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium, or Janssen Research & Development, LLC, Raritan, NJ, USA, or Janssen Research and Development LLC, Titusville, NJ, USA, and all own stock/stock options in the company.Dr. Streffer is a former employee of Janssen Pharmaceutica NV and is currently affiliated with UCB Biopharma, Belgium, and with a research advisory role at Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, and collects no consulting fees and receives no research funding.Dr. Tesseur is a former employee of Janssen Pharmaceutica NV and is currently affiliated with UCB Biopharma, Belgium, and has nothing to disclose.Dr. Tritsmans is a former employee of Janssen Pharmaceutica NV and reports no disclosures.Dr. Engelborghs is employed at the Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, and at the Department of Neurology and Center for Neurosciences, UZ Brussel, and Vrije Universiteit Brussel (VUB), Brussels, Belgium, and reports research funding from Janssen Pharmaceutica NV and ADx Neurosciences (paid to institution).